Abstract
The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.
| Original language | English |
|---|---|
| Pages (from-to) | 367-373 |
| Number of pages | 7 |
| Journal | Diabetes and Metabolism Journal |
| Volume | 41 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 Oct 2017 |
Bibliographical note
Publisher Copyright:© 2017 Korean Diabetes Association.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clinical practice guideline
- Diabetes mellitus
- Hypoglycemic agents
- Insulin
- Korea
- Type 2
Fingerprint
Dive into the research topics of 'Insulin therapy for adult patients with type 2 diabetes mellitus: A position statement of the Korean diabetes association, 2017'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver